Depression obsessive-compulsive disorder and

The enantiomerically pure 3-arylglutaric ester are precursors for the synthesis of (—)-paroxetine [10], a selective serotonin reuptake inhibitor used in the treatment of depression, obsessive compulsive disorder, and panic, and (i )-Baclofen [11], a GABAb receptor agonist, which is used cHnically in the treatment of spasticity (Chart 5.1). 

It is indicated in the treatment of depression, obsessive compulsive disorder and panic disorder. 

It is important to screen patients for co-occurring mental disorders, and their presence may become more apparent during the stabilization or maintenance phases of schizophrenia treatment. Examples include substance abuse disorders, depression, obsessive-compulsive disorder, and panic disorder. As co-occurring disorders will limit symptom and functional improvement and increase the risk of relapse, it is critical that they be appropriately treated. Pharmacological and nonpharmacological interventions specific for the co-occurring disorder should be implemented in combination with evidence-based treatment for schizophrenia. 

The SSRIs are proven treatments for depression, obsessive-compulsive disorder, and panic disorder and are helpful in a variety of other conditions as well. The most substantial benefit to the SSRIs compared with the TCAs is their reduced adverse-effect profile and the fact that they are better tolerated. Although the SSRIs have become the most commonly prescribed drugs for depression, there are clinical situations in which TCAs may be more appropriate (e.g., melancholic depression). Meaningful differences between the individual SSRIs are largely related to their pharmacokinetics, metabolism to active metabolites, inhibition of CYP isoforms, effect of drug-drug interactions, and the half-life of the individual SSRI. 

In 1987, the FDA approved the SRRI fluoxetine (Prozac) for treatment of depression, obsessive-compulsive disorder, and bulimia nervosa. Within 2 years of its approval, 65,000 Prozac prescriptions were written every month in the United States. It had become the most widely prescribed drug in the country. Other SSRls are sertraline (Zoloft) and paroxetine (Paxil). 

Antidepressants are small heterocyclic molecules entering the circulation after oral administration and passing the blood-brain barrier to bind at numerous specific sites in the brain. They are used for treatment of depression, panic disorders, generalized anxiety disorder, social phobia, obsessive compulsive disorder, and other psychiatric disorders and nonpsychiatric states. 

Zoloft (Sertraline) Depression Obsessive-compulsive disorders Panic Post traumatic stress disorder 2.0 0.7 1996 - EU and US Once daily... 

Antidepressant drugs, such as the tricyclic antidepressants and the selective serotonin reuptake inhibitors (SSRIs), are very important for the treatment of psychotic depression (see Chapter 34). They have been shown to be effective when used in the treatment of several anxiety disorders, including general anxiety, obsessive-compulsive disorder, and several phobias, including agoraphobia. Because the SSRIs are less toxic than the tricyclic antidepressants, their use in the treatment of anxiety is safer and less likely to produce serious side effects. 

In 1987, the FDA approved the drug fluoxetine (Prozac) for use in the treatment of major depression. Fluoxetine belongs to a class of agents referred to as selective serotonin reuptake inhibitors (SSRIs). The SSRIs now include sertraline (Zoloft), fiuvoxamine (Luvox), paroxetine (Paxil), and citalopram (Celexa). Fiuvoxamine is approved for use only in obsessive-compulsive disorder and is not discussed in this chapter. 

Sertraline is manufactured by Pfizer under the name Zoloft, in three dosages 25,50, and 100 mg. Zoloft is prescribed for depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, and post-traumatic stress disorder. Sertraline is also used to treat obsessive-compulsive disorder in children. 

Bher P, Bergeron R, Hebert C Differential effectiveness of pindolol addition in treatment-resistant obsessive-compulsive disorder and depression. Poster No. 7, New Chnical Drug Evaluation Unit (NCDEU) Program, 35th Annual Meeting, Orlando, FL, May 31-June 3, 1995... 

Hu Po is sweet and neutral, and enters the blood level of the Heart and Liver. It is particularly effective in sedating the Shen and removing congealed blood. It treats palpitations and restlessness due to blood stagnation. It is used in treating severe and persistent heart and mental disorders such as coronary heart disease, phobia, obsessive-compulsive disorder and manic depression. 

FIGURE 7—33. Mechanism of action of buspirone augmentation—pact 3. Shown here is how buspirone potentiates ineffective SSRI action at 5HT1A somatodendritic autoreceptors, resulting in the desired disinhibition of the 5HT neuron. This combination of 5HT1A agonists plus SSRIs may be more effective, not only in depression but also in other disorders treated by SSRIs, such as obsessive-compulsive disorder and panic. 

Perhaps the most commonly used example of the serotonin 2A strategy is the combination of an SSRI with trazodone. Clinicians have long recognized that trazodone will improve the agitation and insomnia often associated with SSRIs, allow high doses of the SSRI to be given, and consequently boost the efficacy of the SSRI not only in depression, but also in obsessive-compulsive disorder and other anxiety disorders. Thus, both types of bad math are in play here. 

Five women using the Norplant system developed major depression, two of whom also developed obsessive-compulsive disorder and one of whom also developed agoraphobia (28). They had no prior psychiatric history but developed major depression within 1-3 months after insertion of Norplant. The depression worsened over time and in all cases resolved within 1-2 months after removal of Norplant. There was no recurrence of depression after 7-8 months in four cases available for follow-up. In addition to major depression, obsessive-compulsive disorder developed in two women and symptoms of agoraphobia developed in one woman during Norplant treatment, which resolved after removal. 

Den Boer, J. A. and Westenberg, H. G. M. Serotonergic compounds in panic disorder, obsessive compulsive disorder and anxious depression. Hum. Psychopharmacol. 10 (Suppl. 3) (1995) S173-184. 

Olanzapine has been compared with placebo in different mental disorders, including the non-approved indications of psychotic depression, Alzheimer s disease, obsessive-compulsive disorder, and alcohol dependence. 

Aquizerate, B., Cuny, E., Martin-Guehl, C., Guehl, D., Amieva, H., Benazzouz, A., et al. (2004). Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Journal of Neurosurgery, 101, 682-686. 

---